Later response: (could not get PDF download)
Daridorexant and Rapamycin
Executive summary
This report assumes no specific patient details have been provided. It therefore analyses the combination in general adult practice, with particular attention to the two most plausible rapamycin contexts: approved oral sirolimus use for renal-transplant immunosuppression or lymphangioleiomyomatosis, and off-label low-dose use for longevity/healthspan, where evidence is much thinner and dosing is not standardised. For daridorexant, the analysis refers to Quviviq as licensed for adult insomnia.
The key conclusion is that the main clinically relevant interaction concern runs from daridorexant to sirolimus, not the other way round. Daridorexant is primarily metabolised by CYP3A4, but at the 50 mg dose it also behaves as a mild CYP3A4 inhibitor and a mild P-glycoprotein inhibitor in human interaction studies; sirolimus is a CYP3A4 and P-gp substrate with a narrow therapeutic window and trough-guided dosing. That makes a modest rise in sirolimus exposure biologically plausible, especially with daridorexant 50 mg, even though a dedicated daridorexant–sirolimus clinical trial has not been published. By contrast, sirolimus is not expected to inhibit CYP3A4 meaningfully in vivo, so a major effect of sirolimus on daridorexant exposure is unlikely.
In practical terms, if both drugs are used together, the lowest-friction and lowest-uncertainty strategy is usually to keep sirolimus on a stable daytime schedule with a consistent food pattern, and to use daridorexant only at bedtime. For patients on daily sirolimus with target troughs, daridorexant 25 mg nightly is the more conservative starting point; moving to 50 mg nightly should prompt stronger consideration of sirolimus trough monitoring, especially if there is hepatic impairment, older age, other CYP3A/P-gp interacting drugs, or early adverse effects such as mouth ulcers, diarrhoea, oedema, proteinuria, cytopenias, or pulmonary symptoms. Because sirolimus has a long half-life of about 62 hours, any clearance change may take roughly one to two weeks to become fully visible in troughs, which mirrors the label recommendation to wait 7–14 days before re-adjusting maintenance doses after changes.
The evidence base is asymmetric. Daridorexant has good randomised-trial evidence for improving sleep onset, sleep maintenance, and—at 50 mg—daytime functioning, with extension data suggesting benefit and tolerability up to 12 months, and low evidence of withdrawal or physical dependence. Sirolimus has strong evidence in its approved specialist indications, especially LAM and renal-transplant immunosuppression, but its off-label longevity use remains unproven in humans despite encouraging animal data and a growing body of small human studies. That difference matters: the risk tolerance for accepting a possible interaction is much higher in a transplant or LAM patient than in a healthy person self-experimenting with off-label rapamycin.
Clinical role and mechanism of each drug
Quviviq
Daridorexant is a dual orexin receptor antagonist that blocks OX1R and OX2R, reducing the brain’s wake-promoting orexin signal rather than producing broad GABAergic sedation. Its formal indication is the treatment of adult insomnia characterised by difficulties with sleep onset and/or sleep maintenance. In the UK, NICE recommends daridorexant for long-term insomnia only when symptoms persist for at least three nights per week for at least three months, daytime functioning is considerably affected, and CBT-I has failed, is unavailable, or is unsuitable.
The best evidence for daridorexant comes from two Phase III, three-month, placebo-controlled trials involving 1,854 adults with DSM-5 insomnia. In Study 1, both 25 mg and 50 mg improved objective sleep latency and wake after sleep onset versus placebo; the 50 mg dose also showed the clearest improvement in patient-reported total sleep time and daytime functioning. In the 40-week blinded extension, treatment-emergent adverse events were broadly similar across groups, and improvements in sleep and daytime functioning were maintained, again most clearly with 50 mg.
Off-label or emerging uses of daridorexant are much less established. The literature reviewed here suggests exploratory use in insomnia with mild untreated obstructive sleep apnoea, in substance use disorders, and in ordinary clinical practice as a replacement for older hypnotics or other off-label sedating drugs. Those signals are interesting, but the evidence is preliminary and does not create a second established indication.
Rapamycin
Rapamycin in oral systemic practice usually means sirolimus, marketed as Rapamune. Mechanistically, sirolimus binds FKBP-12 and the resulting complex inhibits mTOR, suppressing cytokine-driven T-cell proliferation and antibody production. In LAM, where loss of TSC gene function activates mTOR signalling, sirolimus inhibits that dysregulated pathway and reduces LAM-cell proliferation.
Its approved uses are narrower but high stakes. In the US label, sirolimus is indicated for prophylaxis of organ rejection in low- to moderate-immunologic-risk renal-transplant recipients and for treatment of lymphangioleiomyomatosis. The US label also carries a boxed warning that use is not recommended in liver or lung transplant patients because of adverse outcomes in those settings. In Europe, the product information similarly supports renal-transplant use and sporadic LAM under specialist supervision.
In approved indications, the benefits are clear. In renal transplantation, sirolimus reduces acute rejection, and in LAM it stabilised lung function over 12 months: in the pivotal trial, the FEV1 slope was -12 mL/month on placebo versus +1 mL/month on sirolimus, with an absolute between-group FEV1 difference of 153 mL over the treatment year. After discontinuation, the decline in lung function resumed, which is consistent with a suppressive rather than curative effect.
Off-label systemic sirolimus has become prominent in longevity/healthspan medicine, but the evidence remains uncertain. Reviews published in 2024–2025 conclude that while rapamycin and rapalogs have compelling preclinical evidence, the clinical evidence in healthy adults is not yet sufficient to establish lifespan or healthspan benefit. The longer PEARL trial suggests that intermittent low-dose rapamycin was relatively safe over 48 weeks and showed some signals in lean mass and wellbeing, but that is still far from proving a meaningful clinical net benefit for routine healthy-ageing use.
Dosing, pharmacokinetics, and monitoring
Daridorexant is usually simple to dose; sirolimus is not. That difference is central to the combination problem: daridorexant is a fixed-range nightly hypnotic, whereas sirolimus is often a specialist, concentration-controlled drug in which timing, food consistency, interacting medicines, and follow-up troughs all matter.
Daridorexant is taken 25–50 mg once nightly, within 30 minutes of going to bed, with at least 7 hours before planned awakening. It can be taken with or without food, but a large meal delays onset. Its Tmax is 1–2 hours, absolute bioavailability is 62%, its terminal half-life is about 8 hours, and it shows no accumulation with repeated dosing. It is primarily metabolised by CYP3A4. No dose adjustment is required in renal impairment or in most older adults, but the recommended dose is 25 mg with moderate CYP3A4 inhibitors and in moderate hepatic impairment; use is not recommended in severe hepatic impairment. European labelling treats strong CYP3A4 inhibitors as contraindicated, whereas US labelling says to avoid them.
Sirolimus is administered once daily and should be taken consistently with or without food. In low- to moderate-risk renal transplant patients, the US label gives a typical regimen of a 6 mg loading dose on day 1 followed by 2 mg daily; a higher-intensity transplant regimen uses up to a 15 mg loading dose followed by 5 mg daily with cyclosporine, but the label notes no efficacy advantage of that higher maintenance dose over the 2 mg regimen and a worse overall safety profile. In LAM, the initial dose is typically 2 mg/day, with trough-guided adjustment to 5–15 ng/mL. In transplant regimens with cyclosporine, sirolimus is recommended 4 hours after cyclosporine.
Pharmacokinetically, sirolimus is much “stickier” than daridorexant. Oral sirolimus has low systemic availability; tablet bioavailability is about 27% higher than the solution, and high-fat meals increase exposure. It is extensively distributed into blood elements, about 92% protein bound, metabolised by CYP3A4, and is also a P-gp substrate. The terminal half-life after multiple dosing is about 62 ± 16 hours, which is why the label advises waiting 7–14 days after maintenance-dose changes before making further adjustments. Renal impairment does not require dose adjustment, but hepatic impairment does: the maintenance dose should be reduced by about one third in mild-to-moderate hepatic impairment and about one half in severe impairment, with close whole-blood trough monitoring.
For daridorexant, monitoring is mainly clinical rather than laboratory-based: next-day impairment, unusual sleep behaviours, worsening depression/suicidality, respiratory status in vulnerable patients, and adequacy of response. The label advises reassessing for underlying comorbidity if insomnia does not remit after 7–10 days, and UK prescribing support documents advise review within three months with discontinuation if response is inadequate. Sirolimus is very different: therapeutic drug monitoring is routine, with troughs measured 10–20 days after starting LAM therapy, after dose or interaction changes, and then at least every three months once stable; the official product information also recommends periodic monitoring of urinary protein and lipids, while specialist transplant pathways commonly monitor U&Es, LFTs, blood pressure, full blood count, and lipids at clinic visits.
Comparison table
| Drug |
Main benefits |
Main disadvantages |
Approved indication and off-label use |
Typical adult dosing and key adjustments |
Monitoring, major interactions, and contraindications |
| Daridorexant |
Improves sleep onset and sleep maintenance; 50 mg also improved daytime functioning in Phase III trials and improvements were maintained up to 12 months in extension data. |
Somnolence/daytime impairment, driving impairment after initial dosing, headache, dizziness, nausea, risk of complex sleep behaviours, sleep paralysis/hallucinations, caution in depression and respiratory disease. |
Approved: adult insomnia with difficulty initiating and/or maintaining sleep. Off-label/emerging: exploratory use in insomnia with mild OSA, SUDs, and ordinary practice switches from older hypnotics; evidence remains preliminary. |
25–50 mg once nightly within 30 minutes of bed, with at least 7 hours before waking. Use 25 mg with moderate CYP3A4 inhibitors or moderate hepatic impairment. No adjustment in renal impairment or most patients >65, but falls/somnolence risk increases with age. Severe hepatic impairment: not recommended. |
Clinical monitoring rather than routine labs; reassess if insomnia persists after 7–10 days and review within about 3 months in UK practice. Avoid alcohol; caution with CNS depressants. Strong CYP3A4 inhibitors: contraindicated in EU / avoid in US. Narcolepsy is a contraindication. Daridorexant 50 mg is a mild CYP3A4 and P-gp inhibitor. |
| Sirolimus |
Proven benefit in renal-transplant immunosuppression and in LAM, where it stabilises FEV1 decline and lowers VEGF-D. |
Infection and malignancy risk from immunosuppression; hyperlipidaemia, oedema, hypertension, diarrhoea, stomatitis/mouth ulcers, cytopenias, impaired wound healing, proteinuria, interstitial pneumonitis/ILD, fertility concerns. |
Approved: renal-transplant rejection prophylaxis and LAM/S-LAM. Off-label: longevity/healthspan and other specialist uses, but healthy-ageing efficacy is not established. |
Transplant: often 6 mg loading then 2 mg daily, or higher-intensity 15 mg loading then 5 mg daily in some regimens; LAM: typically 2 mg daily with trough target 5–15 ng/mL. Renal impairment: no adjustment. Hepatic impairment: reduce maintenance dose and monitor troughs closely. |
Therapeutic drug monitoring is routine; after dose changes wait 7–14 days before re-adjusting, and once stable monitor at least every 3 months. Monitor proteinuria, lipids, and clinically for infection, wound healing, and pulmonary toxicity; transplant protocols often add U&Es, LFTs, FBC, BP. Strong CYP3A4/P-gp inhibitors and inducers can markedly alter levels; grapefruit must be avoided. Hypersensitivity is a contraindication. |
Benefits and disadvantages in real use
For daridorexant alone, the most persuasive benefit is that it offers a mechanistically newer insomnia treatment that improves objective and subjective sleep outcomes without the same benzodiazepine-style dependence pattern. The extension study reported no signal of drug-induced next-morning sleepiness on average, no withdrawal-related syndrome, and no rebound-type discontinuation effect beyond the expected loss of benefit once treatment stopped. That does not make it risk-free, but it does distinguish it from older hypnotic classes.
Its disadvantages are mostly neurological and behavioural rather than systemic laboratory toxicities. Daridorexant can impair next-morning driving, particularly after the first few nights, and European labelling recommends roughly 9 hours between dosing and driving or machine use. Complex sleep behaviours, hypnagogic/hypnopompic hallucinations, sleep paralysis, and worsening depression or suicidal ideation are uncommon but clinically important reasons to stop or re-evaluate therapy.
For sirolimus alone, benefits are strongest when the indication is strong. In transplant practice, its benefit is prevention of rejection; in LAM, it slows decline in lung function and improves biomarker and physiological measures during treatment. Those are important, disease-modifying effects in genuinely serious conditions.
The disadvantages of sirolimus are broader and often cumulative. The long-standing safety profile includes hyperlipidaemia, oedema, stomatitis, diarrhoea, acne, anaemia, thrombocytopenia, hypertension, and infection risk, while more serious concerns include impaired wound healing, interstitial lung disease/non-infectious pneumonitis, proteinuria/nephrotic syndrome, and malignancy risk associated with immunosuppression. Long-term treatment also requires ongoing review because benefit and risk are concentration-dependent.
For off-label longevity use, the balance is much less favourable than social-media enthusiasm often suggests. Human studies in healthy or normative-ageing adults remain small, heterogeneous, and focused on biomarkers or intermediate outcomes; recent reviews explicitly conclude that clinical evidence is not yet sufficient to support routine use for lifespan or healthspan extension. That matters when judging the acceptable interaction risk with daridorexant: uncertainty is much easier to justify in LAM or transplantation than in preventive self-experimentation.
Concurrent use and sequencing analysis
There is no high-quality direct clinical trial in the reviewed sources testing daridorexant plus sirolimus head-to-head. The most defensible analysis therefore comes from combining official interaction data with known half-lives and route-of-clearance logic. A UK interaction source explicitly predicts that daridorexant may increase sirolimus exposure and advises caution; that prediction is mechanistically consistent with the product information for both drugs.
Pharmacokinetic interaction
The highest-confidence pharmacokinetic concern is daridorexant increasing sirolimus exposure. At 50 mg, daridorexant increased midazolam AUC by 42%, showing mild CYP3A4 inhibition, and increased dabigatran AUC/Cmax by 42%/29%, showing mild P-gp inhibition. Because sirolimus is a CYP3A4/P-gp substrate and its toxicity and efficacy are tied to narrow trough targets, even a “mild” interaction can matter more than it would for an ordinary drug. The probable real-world result is not a catastrophic interaction, but rather a possible upward drift in sirolimus levels and toxicity risk, with greatest concern in patients already near the upper end of their therapeutic range.
The reverse direction is much less concerning. Although sirolimus inhibits several CYP enzymes in vitro, the European product information says it is not expected to inhibit these isozymes in vivo at therapeutic concentrations. On current evidence, sirolimus itself should therefore be viewed mainly as a victim of CYP3A/P-gp interactions rather than a major perpetrator against daridorexant.
Dose matters. The European daridorexant label reports that 25 mg did not affect midazolam pharmacokinetics, whereas 50 mg did. That makes 25 mg the more attractive starting dose whenever sirolimus exposure must be carefully preserved, especially in transplant or LAM patients on specialist trough targets.
Pharmacodynamic interaction
There is no strong direct pharmacodynamic synergy analogous to combining two sedatives, because sirolimus is not a CNS depressant. Daridorexant is the drug that produces sleepiness and next-day psychomotor impairment. However, there are still indirect clinically relevant overlaps: daridorexant can increase falls, drowsiness, or unusual nocturnal behaviours, while sirolimus can impair wound healing and increase infection risk; together, that means a nocturnal injury may be harder to recover from. In addition, sirolimus-related fatigue, oedema, mouth ulcers, diarrhoea, or pneumonitis may worsen the very daytime function that insomnia treatment is meant to improve.
Preclinical work adds an interesting but still non-actionable biological note. Orexin signalling can activate mTORC1, and in a mouse model of tuberous sclerosis complex, rapamycin reversed increased orexin expression and sleep abnormalities. That suggests the orexin and mTOR systems do interact biologically, but it does not show that taking sirolimus and daridorexant together is synergistic, beneficial, or safer in humans.
Sequence of dosing
Because daridorexant has a half-life of about 8 hours, sequence matters mostly on the daridorexant side. Because sirolimus has a half-life of about 62 hours, sequence by a few hours matters much less once sirolimus is at steady state. That means changing the order of the tablets on a given day is not likely to abolish interaction risk in a patient on chronic daily sirolimus; the bigger determinant is whether daridorexant 50 mg is given nightly and whether its addition is followed by sirolimus trough monitoring.
If sirolimus is taken first in the daytime and daridorexant is taken later at bedtime, sirolimus absorption is likely to be largely complete before daridorexant reaches peak concentrations, because sirolimus peaks within roughly 1–3.5 hours and daridorexant within 1–2 hours after its own dose. This sequence is therefore the most pharmacologically tidy, especially for people on once-weekly off-label rapamycin, because it reduces the chance that daridorexant will inhibit the intestinal first-pass handling of the sirolimus dose that same day.
If daridorexant is taken first at bedtime and sirolimus is taken the next morning, daridorexant is still pharmacologically present; after around one half-life, about half of systemic exposure remains. That creates a more plausible window for mild CYP3A4/P-gp inhibition during the next sirolimus dose’s absorption and first-pass metabolism. This is an inference from half-life and interaction data, not a direct clinical study, but it is the most plausible reason to prefer a consistent daytime sirolimus schedule rather than “morning-after-bedtime-hypnotic” dosing when the schedule is flexible.
For patients on approved daily sirolimus, sequence optimisation is much less powerful than good monitoring, because sirolimus exposure changes slowly. If daridorexant 50 mg is started, withheld, or dose-escalated, the prudent response is not just shifting clock time by two or three hours; it is to review the full interaction burden and, where clinically important, re-check sirolimus troughs after about 7–14 days, mirroring how the label handles other changes that affect sirolimus steady state.
Sequencing scenarios
| Scenario |
Likely interaction significance |
Most sensible approach |
| Daily sirolimus already established, daridorexant 25 mg added at bedtime |
Lower interaction concern; daridorexant 25 mg showed no CYP3A4 effect on midazolam in the label study, but sirolimus still has a narrow target window. |
Reasonable starting combination if insomnia treatment is needed; keep sirolimus timing and food pattern unchanged, and monitor clinically for sirolimus toxicity. |
| Daily sirolimus already established, daridorexant escalated or started at 50 mg |
Higher concern; daridorexant 50 mg is a mild CYP3A4 and P-gp inhibitor, so sirolimus exposure may rise. |
Prefer fixed daytime sirolimus and bedtime daridorexant; consider sirolimus trough and safety labs after about 7–14 days if the sirolimus target range is clinically important. |
| Off-label weekly rapamycin with nightly daridorexant |
Uncertain and formulation-sensitive; compounded low-dose rapamycin has shown variable bioavailability, and human benefit for ageing is unproven. |
Avoid casual self-experimentation; if combination is pursued, keep rapamycin on a fixed daytime slot before the bedtime daridorexant dose, not as an ad hoc bedtime add-on. |
| Sirolimus plus cyclosporine plus daridorexant |
Often more important than the direct sirolimus–daridorexant interaction, because cyclosporine is a moderate CYP3A4 inhibitor for daridorexant and also changes sirolimus handling. |
Daridorexant should generally be capped at 25 mg, and transplant-specialist review is advisable before adding it. |
Approved specialist use
Off-label healthy-ageing use
25 mg nightly
50 mg nightly
Need both drugs?
Why is sirolimus being used?
Keep sirolimus regimen stable
Reassess indication and clinician oversight
Daridorexant dose
Lower PK interaction concern
Higher chance of raising sirolimus exposure
Give daridorexant only at bedtime
Keep sirolimus at a fixed daytime time and consistent food state
Check sirolimus trough after about 7 to 14 days
Clinical monitoring for ulcers, oedema, infections, cough, diarrhoea
Adjust sirolimus only under specialist direction
Monitor daytime sedation, falls, mood changes, parasomnias
Do not assume anti-ageing benefit is proven
Show code
The flowchart summarises the most defensible sequencing logic from the available evidence: bedtime daridorexant, daytime sirolimus, and stronger monitoring when daridorexant 50 mg is involved. That strategy is based on daridorexant’s short half-life and mild inhibitor effects, together with sirolimus’s long half-life and concentration-guided dosing.
Practical recommendations and limitations
For clinicians, the first step is to separate patients into two groups: those taking sirolimus for a high-value approved indication and those taking it off-label for longevity. In the first group, adding daridorexant can be reasonable if insomnia is clinically important; starting at 25 mg nightly is the safer option when sirolimus is part of the background regimen, especially in older adults, people with hepatic impairment, or those on additional CYP3A/P-gp interactors such as azoles, macrolides, diltiazem/verapamil, rifampicin, cannabidiol, or cyclosporine. In the second group, the evidential bar should be higher because the rapamycin benefit itself is not established.
If both drugs are prescribed together, the most practical dose strategy is usually this: keep sirolimus at a fixed daytime time and a fixed food relationship, and take daridorexant only when ready for bed, avoiding alcohol and large evening meals. If daridorexant is started, stepped up to 50 mg, or stopped in a patient with clinically meaningful sirolimus trough targets, a sirolimus trough after about 7–14 days is a sensible risk-mitigation step, even though this specific interaction interval has not been formally trialled, because that is the same time frame the sirolimus label uses when steady-state levels change.
For patients, the most important operational rules are simple. Daridorexant should be taken within 30 minutes of bedtime, only when there are at least 7 hours available before getting up; alcohol should be avoided, and if marked morning grogginess, unusual behaviours in sleep, hallucinations, or low mood appear, the drug should be reviewed. Sirolimus should be taken at the same time each day, with the same relation to food, and grapefruit should be avoided. Any fever, new mouth ulcers, worsening diarrhoea, increasing swelling, cough, breathlessness, bruising, or reduced urine output warrants clinical review because those are more compatible with sirolimus toxicity than with daridorexant.
A special caution applies if the patient is on a transplant regimen that also includes cyclosporine. The daridorexant label explicitly lists cyclosporine as a moderate CYP3A4 inhibitor, which means the recommended daridorexant dose is 25 mg, not 50 mg. In other words, in many transplant patients the most important determinant of daridorexant exposure may be the rest of the immunosuppressive regimen, not sirolimus alone.
Open questions and limitations
The most important limitation is straightforward: there is no dedicated daridorexant–sirolimus clinical interaction study or robust published case series in the sources reviewed. The sequencing and dose recommendations above therefore rely on official pharmacology data, interaction studies with probe substrates, half-life reasoning, and specialist monitoring principles, rather than a direct clinical evidence base.
There is also persistent uncertainty around off-label rapamycin dosing for longevity, because human studies have used different products and schedules, and even recent real-world work has found variability in low-dose bioavailability. That makes any universal advice on “safe” at-home pairing with daridorexant particularly weak. For that population, the prudent interpretation is not that the combination is known to be dangerous, but that the benefit side of the equation is still too uncertain to justify complacency about interaction risk.